Zofran (Ondansetron) 4 mg and 8 mg ODT: Prescription 5-HT3 Serotonin Antagonist for Chemotherapy-Induced and Post-Operative Nausea

Information last reviewed: May 2026 — for educational purposes only.

Zofran (ondansetron) is a selective 5-HT3 (serotonin type 3) receptor antagonist — the first of what became a highly effective antiemetic drug class. Ondansetron works by blocking 5-HT3 receptors both centrally (in the vomiting centre and area postrema) and peripherally (in the vagal afferents of the GI tract). Serotonin released from enterochromaffin cells in the gut during cytotoxic chemotherapy or radiation triggers the vomiting reflex via 5-HT3 receptors — ondansetron disrupts this signal, providing potent antiemetic coverage. It does not cause EPS or tardive dyskinesia (because it does not block D2 receptors), and it has minimal sedation, setting it apart from older antiemetics.

Ondansetron is FDA-approved for: prevention and treatment of nausea and vomiting induced by chemotherapy (chemotherapy-induced nausea and vomiting — CINV); radiation-induced nausea and vomiting; and post-operative nausea and vomiting (PONV). It is also used extensively off-label for nausea and vomiting in pregnancy (particularly hyperemesis gravidarum) and for acute gastroenteritis in children and adults.

What Is Ondansetron?

Ondansetron (brand: Zofran, Zuplenz) is a carbazole derivative that selectively and competitively blocks 5-HT3 serotonin receptors. By blocking peripheral gut vagal 5-HT3 receptors, it prevents the afferent nerve signal from reaching the vomiting centre. By blocking central 5-HT3 receptors in the area postrema, it suppresses centrally triggered vomiting. Unlike D2 antagonist antiemetics, it does not affect dopamine pathways and therefore has no EPS risk — making it far better tolerated for most patients. Common side effects include headache, constipation, and mild fatigue. QTc interval prolongation is a dose-related cardiac concern (avoid high-dose IV ondansetron in patients with cardiac conduction abnormalities or on QTc-prolonging drugs).

Prescription Status

Ondansetron is prescription-only in the United States. It is not available OTC. Generic ondansetron tablets and ODTs are now widely available and are significantly cheaper than brand-name Zofran. It is on the WHO Model List of Essential Medicines.

Strengths and Available Forms

• 4 mg tablets — adults: 4 mg every 8 hours; paediatric use for CINV and gastroenteritis
• 8 mg tablets — most common adult antiemetic dose; for moderately emetogenic chemotherapy: 8 mg 30 min before + 8 mg 8 hours later; then every 8 hours for 1–2 days post-chemotherapy
• 4 mg orally disintegrating tablets (ODT) — dissolves on tongue without water; particularly useful for nausea patients who cannot swallow; identical efficacy to oral tablets
• 8 mg orally disintegrating tablets (ODT) — same convenience as 4 mg ODT at higher dose; preferred by many nausea patients
• 4 mg/2 mL and 32 mg/50 mL IV solutions — hospital use; for PONV: single 4 mg IV dose; for CINV: 0.15 mg/kg IV Q4H x3 or 32 mg single dose (though 32 mg single dose withdrawn due to QTc concerns); slow IV infusion over 15 minutes
• Zuplenz 4 mg and 8 mg oral soluble film — dissolves in the mouth like an ODT strip; convenient for travel or vomiting patients

For PONV prophylaxis: 4 mg IV administered near the end of surgery is the standard dose. For pregnancy nausea (off-label): 4–8 mg orally 2–3 times daily. For gastroenteritis nausea (off-label): single 4 mg or 8 mg ODT dose significantly reduces vomiting episodes in randomised trials.

Price of Zofran / Generic Ondansetron

Generic ondansetron tablets and ODTs are available at very affordable prices with good insurance coverage and are accessible through pharmacy discount programs without insurance. Brand-name Zofran is significantly more expensive. The ODT form is slightly more expensive than tablets but not dramatically so in generic form. IV ondansetron for hospital use is also available generically at very low unit cost.

Frequently Asked Questions

Is ondansetron safe to use during pregnancy for morning sickness or hyperemesis gravidarum?

Ondansetron is widely used off-label for nausea and vomiting in pregnancy, particularly when first-line treatments such as pyridoxine-doxylamine (Diclegis/Bonjesta) are insufficient, or in hyperemesis gravidarum. Multiple large studies have found no increased risk of major birth defects overall, but some studies have noted a small signal for oral cleft (cleft palate) with first-trimester exposure. Most obstetric guidelines consider it acceptable for use when the benefit of treating severe pregnancy nausea outweighs the small potential risk. The prescribing physician should make this individualised benefit-risk determination, especially in the first trimester.

Can ondansetron be used for regular nausea and vomiting from illnesses like gastroenteritis?

While not FDA-approved for gastroenteritis, ondansetron is extensively used off-label in emergency departments and paediatric settings to reduce vomiting and prevent dehydration in acute gastroenteritis — with strong supporting evidence from randomised controlled trials. A single 4–8 mg ODT dose in adults, or a weight-based dose in children, significantly reduces vomiting episodes and IV fluid requirements. Its clean side effect profile and ODT convenience make it particularly practical in this setting. A prescription from a physician is still required.

What is QTc prolongation and why does it matter with high-dose ondansetron?

QTc prolongation is an extension of the cardiac electrical repolarisation interval (QT interval, corrected for heart rate) visible on an ECG. When the QTc is prolonged, there is greater risk of a dangerous arrhythmia called Torsades de Pointes (TdP). Ondansetron causes dose-dependent QTc prolongation. Low to moderate doses (4–8 mg oral, 4 mg IV) have very low arrhythmic risk in healthy patients. High-dose IV (single 32 mg IV dose) was withdrawn from labelling due to this concern. Patients with pre-existing QTc prolongation, electrolyte abnormalities (especially hypokalaemia, hypomagnesaemia), or on other QTc-prolonging drugs (e.g., haloperidol, fluconazole, certain antidepressants) should be monitored. For most patients using standard oral doses, QTc risk is clinically negligible.

← Back to Nausea Medications